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CFP10 (25mg/mL); A2,A3 negative controls consisted of
cells cultured with medium alone; B2,B3 positive controls
consisted of cells cultured with Con A (25 mg/mL).
Results: The CFP-10 recombinant protein were obtained and
puriﬁed, In-house ELISPOT IFN-g assay using recombinant
CFP-10 antigen show signiﬁcant high frequencies TB speciﬁc
T-cell responses in patients of active TB with or without
HIV infection. there was 100% consistency to the clinical
manifestation, in the HIV(+) group without clinical TB
disease, the rate of positive tests results was 24.7%.
Our results proved that it is indeed true that some of HIV
positive patient have high frequencies of TB speciﬁc T-cell
responses, it could be used in diagnosis of TB diseases,
and it maybe provide a clue to ﬁnd latent TB infection in
Chinese HIV(+) population.
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Background and Aims: Hemophagocytic syndrome (HPS) is a
fatal complication of severe viral infections such as Epstein-
Barr virus (EBV) and recently, SARS CoV, and H5N1 inﬂuenza.
The pathogenesis of HPS is presumed to result from an
enhanced proinﬂammatory cytokine secretion and systemic
macrophage activation. Previously, we demonstrated that
EBV LMP-1 can activate T-cells and upregulate tumor
necrosis factor-alpha and interferon-gamma, mediated
through the NFkB/ATF5/SAP/ERK signaling, to activate
macrophages. Since peroxisome proliferators activated
receptor (PPAR) agonists, regulators of cholesterol
metabolism, have been shown to exhibit profound effects on
the inhibition of proinﬂammatory cytokines and macrophage
activation through NFkB and AP-1 signaling, we adopted a
PPAR-g agonist, rosiglitazone, for the potential therapy of
HPS using a rabbit model of Herpesvirus papio (HVP, an EBV
homologue)-associated HPS.
Materials and Results: In vitro, rosiglitazone was shown
to inhibit macrophage activation and secretion of tumor
necrosis factor-alpha (TNF-a) through inhibition of NFkB
signaling in THP1 cell line. Different doses of rosiglitazone
were then fed to rabbits after intravenous injection of
5×107 copies of HVP virus at different time courses (7
days and 20 days, respectively) of infection. As compared
to the control group which succumbed consistently at
around one month, the 4mg rosiglitazone-treated group
showed signiﬁcant improvement of survival when fed at
early stage (7 days) of infection (p < 0.01), while a higher
dosage (8mg) is needed to achieve therapeutic effect at
advanced stage (20 days) of infection (p < 0.05). The viral
load, TNFa cytokine levels, and laboratory parameters also
showed signiﬁcant improvement in the rosiglitazone-treated
group.
Conclusion: PPAR agonist, in addition to its therapeutic
effect for metabolic syndrome, appears to represent a
potential regimen of new concept for the control of HPS
associated with severe virus infections.
OL-044 HAV seroprevalence among children with 10 24
month ages in Ulaanbaatar
G. Sarangua1 *, S. Anand1, Ts. Selenge1, A. Bayasgalan1,
D. Naranzul1, B. Bolor1, N. Naranbat1, Y. Dahgwahdorj2,
P. Nyamdawa1. 1Center for Communicable Diseases
of Mongolia, 2Health Sciences University of Mongolia,
Mongolia
Background: HAV infection is high endemicity in Mongolia.
The outbreak of acute HAV infection is regular and
wide outbreak usually within 3 4 years interval. Recently,
Mongolian and Japanese researchers established the
seroprevalence of HAV infection in Mongolian adults almost
100%. So, there is urgently needed the HAV vaccination
program in Mongolia.
Aim of study: To determine the age (month) of start for
universal HAV vaccination.
Method and Subjects: In July and August 2008, there were
selected 953 children ages 11 24 months from Chingiltei
district, Ulaanbaatar. More 600 of them were living in the
Mongolian ger (nomad’s tent less comfortable and sanitary
condition than city’s apartment). In all children had not
manifested acute viral hepatitis. In all serum of selected
children were tested anti-HAV-IgG.
Results: There was detected positive of anti-HAV in 20
children of 951. 19 of them living in ger. The table shows
the results by age and sex.
Age Male Female Total
(months) N Anti-HAV+ N Anti-HAV+ N Anti-HAV+
11 12 71 59 130 0
13 14 104 2 94 2 202 4
15 16 74 1 68 143 1
17 18 70 3 58 1 132 4
19 20 57 1 57 2 117 3
21 22 57 2 48 1 108 2
23 24 77 5 59 141 5
Total 510 14 443 6 953 20
Conclusions: 1. The incidence of HAV infection occurred
from 13 month’s age, after wide outbreak. 2. There
is recommended to start HAV vaccination for children,
who living in uncomfortable hygiene condition, before 13
month’s age.
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The aim of this study was to investigate the prevalence
of beta-herpesvirus (HHV-6 and HHV-7) infections among
the HIV/AIDS, chronic fatigue sindrome (CFS) patients in
comparison with blood donors (BD).
Materials and Methods: 52 patients with HIV/AIDS, 49 CFS
and 150 healthy BD were enrolled in the study. Active
and latent/persistent viral infections determined by nPCR:
the presence of viral genomic sequences in PBL DNA only
was deﬁned as latent/persistent infection; sequences in
PBL DNA and blood plasma DNA was deﬁned as active
infection. Concurrent infection with both HHV-6 and HHV-7
was deﬁned as simultaneous presence of both virus genomic
sequences in DNA sample of patient (isolated from PBL or
blood plasma).
Results: PCR analysis did not reveal a signiﬁcant diference
in the prevalence of latent/persistent HHV-7 infection
